Alogliptin after acute coronary syndrome in patients with type 2 diabetes - Wikidata - awgldk - TriplyDB

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

http://www.wikidata.org/entity/Q28297690

about

Glucagon and heart in type 2 diabetes: new perspectives The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice Diabetes Drugs and Cardiovascular Safety Advances in the treatment of type 2 diabetes: impact of dulaglutide The EMPA-REG outcome study: critical appraisal and potential clinical implications The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies Incretin-Based Therapy for Prevention of Diabetic Vascular Complications The metabolic vascular syndrome - guide to an individualized treatment Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus New Insights in the Diagnosis and Treatment of Heart Failure Drugs for type 2 diabetes: role in the regulation of bone metabolism Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Vascular repair strategies in type 2 diabetes: novel insights Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease Incretin physiology and pathophysiology from an Asian perspective DPP4 in Diabetes Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists Origin and therapy for hypertriglyceridaemia in type 2 diabetes Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke Safety of dipeptidyl peptidase 4 inhibitors: a perspective review

P2860

Q26738580-EEAD63FF-EAC2-4771-AEBF-741099329BCB Q26738873-93DBCE2F-A3FE-44D5-AFC1-82AA286BDB80 Q26739999-65707BD4-A976-4305-8F09-A75B3E9D7AAB Q26740171-4AA956CA-5CB5-4953-AF3D-EFBF9EC9930E Q26740247-82803FB2-3E84-4EAD-A785-C0C132A8F2E2 Q26740253-54621554-9FE9-4AA2-96BE-4D05751834BC Q26740443-95D32FF2-DB5C-4345-9374-232584365F1A Q26741067-33409E52-9F7F-4D9C-88B9-01CCDB671933 Q26741860-C93DB61B-CD45-4FEB-B0C3-526397D298FE Q26746085-1B6FFF80-5C21-4636-BF6C-1B5EEBD3888F Q26746220-2A16C037-B7A8-4E41-A54A-F3645AF8FA43 Q26748742-FEC182C0-1A76-435F-A821-D087BD17CF61 Q26748870-EB02DB71-D02C-4D87-B08E-D1686618E276 Q26749176-2E18562A-9188-43A6-9B6F-1DB504608FB0 Q26750510-6537DA13-2029-4BD6-942B-0AF4E12FE2A8 Q26752255-AD2E9638-902C-4ED3-94FE-63CAF1035598 Q26765047-CDFA2DB9-8E1F-43F6-8268-B678585EFA6F Q26765470-BBBF08F1-C2E0-4801-9B8E-FC572864FBD0 Q26767142-6434A9F7-63F6-4BC3-9477-495C89A19FAE Q26767260-FC532AEA-74FD-4EB9-97C4-1FE0DE2FC0D5 Q26774021-269888BD-1557-4F35-899E-93926142CCD2 Q26774884-3C9C25BA-9371-404C-9593-8EBA2FFF05A5 Q26775763-6C183536-FB8F-4FEC-BDBD-E9153B3BFC6E Q26777177-36820B96-A8FA-4992-9C49-68F3919BDB20 Q26777994-D5B906A6-1826-480F-8958-68C782A2F8D7 Q26778658-C2277EFF-B6EA-45B5-BD4B-A68E2BE97781 Q26781269-E4C583C0-BBB4-4840-BB81-9E5BB6FCC350 Q26784211-3BFA4FF8-2663-45BC-9F46-B89ABB49C6D8 Q26784454-1A241405-7E52-452E-8854-89E598EE0558 Q26784623-7DE55C03-278F-460B-B710-AAC0480920B9 Q26797335-451A5C80-E404-4DD3-9E5E-949B6090444C Q26801121-BEB4ECE9-FEB0-4E67-8E6B-CC628C09F78D Q26823085-9673E6ED-37C8-43C5-84E1-622BB8020B66 Q26824004-0AADEDB8-BC0E-44B3-AEEB-3202CA7DE481 Q26824239-AFF383CD-A6A4-47E5-8E06-B910F13632AF Q26824616-14EA6E9E-52D4-494A-AD72-8D5F42F411F4 Q26829634-8A649DEC-F3B3-485C-8599-801CDB53B548 Q26851797-1B68E22E-B32F-4A64-8612-DE71D095BBB9 Q26861493-0D23D643-EBF5-405A-8351-A4B2D2ED0E16 Q26863262-2DCF57A7-D6F2-4C4D-AE4F-1B4357043102

P2860

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

http://www.wikidata.org/entity/Q28297690

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@ast

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@en

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@nl

type

label

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@ast

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@en

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@nl

prefLabel

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@ast

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@en

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@nl

P1433

Q28297690-41A8BA83-2B55-45DA-8913-41F9B1D7F9D2

P1476

Q28297690-419C2A53-F919-4264-9327-6DD51506DC59

P2093

Q28297690-1170F3B6-70BF-451B-92D2-660B45575C28

Q28297690-2437EC88-A901-48BF-AA80-2B60625313AD

Q28297690-3FEC6F88-FEFD-4D1E-AF9A-DF6A3BED5136

Q28297690-4160F56E-47E4-4B1B-B5CF-0474D570B01F

Q28297690-44468814-68A9-4A41-ABC5-8BF5E7DED083

Q28297690-44A617B6-3B57-4C47-87D6-D55AB8480010

Q28297690-7ECE3A88-A759-47E8-869E-57E11EF0C2BC

Q28297690-A52D9CC2-8059-4B35-A920-753144BF2B2F

Q28297690-BA2031B6-1EEA-4FD0-85FD-04687088DE7E

Q28297690-D629B50C-7CD0-4C65-9975-16965F297EC7

P304

Q28297690-8FF2F2C2-5A02-4E50-8927-BA156CE0955D

P31

Q28297690-46BB7A40-E955-40E1-A9F2-F53A6BB12BC5

P3181

Q28297690-7C7E250E-A00D-49EB-9D70-C48E519FB201

P356

Q28297690-ED91F2A5-F090-4A0F-B25F-68BB0B1F9D32

P407

Q28297690-6E34937E-5A16-4CA2-8DF2-576A8CFE3021

P433

Q28297690-6E9756FD-0B4C-40B2-9EA7-4440809362B6

P478

Q28297690-D4FFD0DE-6BDA-4ACE-A03F-7AE538BD26EB

P50

Q28297690-4FA9F933-92D7-4F96-90D7-14EF619705CA

Q28297690-B7D39DFD-3C8C-4415-8215-55454230E1B5

P577

Q28297690-25E9C3BE-1473-436A-9ADB-C4BE7B3147F9

P698

Q28297690-2DF23808-46CC-468E-B6CC-C27C011421F0

P921

Q28297690-CF82F29A-3B9C-4884-93E5-26171F353B6C

P3181

P356

P1433

The New England Journal of Medicine

P1476

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

@en

P2093

Alfonso T Perez

http://www.w3.org/2001/XMLSchema#string

Christopher P Cannon

http://www.w3.org/2001/XMLSchema#string

Craig Wilson

http://www.w3.org/2001/XMLSchema#string

Cyrus R Mehta

http://www.w3.org/2001/XMLSchema#string

George L Bakris

http://www.w3.org/2001/XMLSchema#string

Penny R Fleck

http://www.w3.org/2001/XMLSchema#string

Richard M Bergenstal

http://www.w3.org/2001/XMLSchema#string

Steven E Nissen

http://www.w3.org/2001/XMLSchema#string

Stuart Kupfer

http://www.w3.org/2001/XMLSchema#string

William B White

http://www.w3.org/2001/XMLSchema#string

P304

1327-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

25631

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1305889

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23992602

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes